There are 2789 resources available
1230P - Elderly patients treated with afatinib in clinical practice: Final results of the GIDEON study in EGFR mutated NSCLC in Germany
Presenter: Wolfgang M Brueckl
Session: ePoster Display
1284P - Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC
Presenter: Bo Gao
Session: ePoster Display
1285P - Final analysis of TORG1936/AMBITIOUS: Phase II study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonia
Presenter: Yuki Sato
Session: ePoster Display
1286P - Senescent immune phenotype (SIP) status predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients
Presenter: Marie Naigeon
Session: ePoster Display
1287P - Immune T-cell subpopulations from the peripheral blood of non-small cell lung cancer patients are associated with the efficacy of anti-PD-1 immunotherapy
Presenter: Jacobo Rogado
Session: ePoster Display
1288P - Mutations in MTOR pathway and response of immune checkpoint inhibitors
Presenter: Lei Cheng
Session: ePoster Display
Resources:
Abstract
1289P - Intracranial response (ICR) following immunotherapy in non-small cell lung cancer (NSCLC) patients with untreated brain metastasis (BM)
Presenter: Birgitte Bjoernhart
Session: ePoster Display
1291P - A phase II study of nivolumab rechallenge therapy in advanced NSCLC patients who responded to prior anti-PD-1/L1 inhibitors: West Japan Oncology Group 9616L
Presenter: Shunsuke Teraoka
Session: ePoster Display
1292P - Two single-arm, multicenter phase-II trials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603/NCCH1703)
Presenter: Ryo Toyozawa
Session: ePoster Display